Paclitaxel albumin (Abraxane®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000392
English
Authors' recommendations:
Paclitaxel albumin (Abraxane®) monotherapy is recommended as an option for use within NHS Wales for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for who standard, anthracycline containing therapy is not indicated.
AWMSG is of the opinion that paclitaxel albumin (Abraxane®) is not suitable for shared care within NHS Wales.
Clinicians should follow the National Institute for Health and Clinical Excellence (NICE) Guidelines CG81 in the consideration of treatment options for metastatic breast cancer.
The Summary of Product Characteristics specifically states that this drug should be used as monotherapy.
In order to limit potential errors, paclitaxel albumin (Abraxane®) should be prescribed by brand as Abraxane®.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=158203&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Breast Neoplasms
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.